Connect Biopharma says Phase 2 trial shows rademikibart cuts COPD treatment failure rate 81% through Week 4
CNTB•Connect Biopharma reported positive preliminary topline results from a global Phase 2 trial, saying rademikibart cut COPD treatment failures by 81% through Week 4 versus placebo.
1. Phase 2 trial results
Connect Biopharma reported positive preliminary topline results from a global Phase 2 trial of rademikibart for acute COPD flare-ups. The company said the drug cut post-flare treatment failures by 81% through Week 4 versus placebo, with fewer repeat medical visits in the month after dosing. It also lowered new moderate-to-severe flare-ups; no return emergency visits or hospitalizations were reported in the treatment arm.
2. Next development steps
Connect Biopharma plans to seek FDA alignment on a Phase 3 registrational program for rademikibart as an add-on COPD therapy. The results have already been presented, and the company scheduled a conference call for 8:00 a.m. ET that day.
